HC Wainwright maintains Buy on Vir Biotechnology, $22 target
HC Wainwright & Co. reiterated a Buy rating on Vir Biotechnology and kept its $22.00 price target.
Story updates
02:32:11 PM UTC
SquawkNews
Ratings actions from Benzinga: GMT) Vir Biotechnology Is Maintained at Buy by HC Wainwright & Co.Ratings actions from Benzinga
02:34:18 PM UTC
SquawkNews
Vir Biotechnology Price Target Raised to $22.00/Share From $20.00 by HC Wainwright & Co.